Most drugs and therapies introduced to date do not perform equally well for all patients, with significant differences in efficacy and safety among individuals. Frequently, a considerable proportion of patients simply do not respond, resulting in wasted therapy costs and no benefit to the patient.
A simple test that can accurately predict whether an individual will respond to a given medication would benefit all patients, clinicians, and reimbursement authorities, as well as create new drug development opportunities for non-responsive patient groups.
Selected webinars
Dr. Hurtado-Lorenzo, VP of Translational Research for the Crohn's & Colitis Foundation, discusses the findings of a major study identifying prognostic indicators that predict whether children with Crohn's disease will develop serious complications such as fibrosis and/or fistulas.
He also discusses the identification of protein biomarkers that determine whether patients would respond to anti-TNF medication in this webinar.
A flexible platform that accelerates your research
Olink's scalable technology offers tailored solutions for all stages of the biomarker workflow, from high-throughput discovery to validation and clinical application.
About Olink®- Part of Thermo Fisher Scientific
Olink’s mission is to accelerate proteomics together with the scientific community, to understand real-time biology and gain actionable insights into human health and disease. Our innovative solutions deliver highly sensitive and accurate protein quantification, giving scientists the power to investigate complex biological processes with precision.
One platform. Endless possibilities.
Explore up to 5,400 proteins with high specificity, transparent data, and the flexibility to answer any research question. Meet the next-generation proteomics platform trusted by the scientific community, from small academic research teams through to leading pharma companies.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.